Print Page

给 医 护 专 业 人 员 的 信
 
Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease (Letter to Healthcare Professionals) (English only)
 
 
 
附件:
  1. Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease (English only)  
Related Information:
The United Kingdom: Febuxostat: updated advice for the treatment of patients wit... 上载于 2023-05-27
Singapore: Risk of cardiovascular events with febuxostat (English only) 上载于 2019-12-11
Canada: Uloric (febuxostat): Increased risk of cardiovascular fatal outcomes (En... 上载于 2019-11-05
Australia: Febuxostat (Adenuric) tablets: Safety advisory – increased risk of de... 上载于 2019-10-02
The United Kingdom: Febuxostat (Adenuric): increased risk of cardiovascular deat... 上载于 2019-07-18
FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (fe... 上载于 2019-02-22
The United States: FDA adds Boxed Warning for increased risk of death with gout ... 上载于 2019-02-22
美国：非布司他：药物安全通讯：美国食物及药物管理局评估与心脏相关死亡风险的增加 上载于 2017-11-16
 
back